UnitedHealth Lifts 2025 Profit Forecast, CEO Eyes Growth In 2026

Reuters
10/28

Oct 28 (Reuters) - UnitedHealth UNH.N on Tuesday raised its annual profit forecast after reporting better-than-expected quarterly earnings as the U.S. health insurer kept medical costs in check.

UnitedHealth shares surged 6% in premarket.

The company earlier this year drastically cut its outlook, which had sent its shares plummeting.

Newly returned CEO Stephen Hemsley has been under pressure to regain investor and consumer trust in the wake of an unexpected surge in medical costs and Americans' anger at the high price of health care.

Hemsley, who has replaced several long-time executives, was brought in earlier this year as part of a management shakeup.

"We remain focused on strengthening performance and positioning for durable and accelerating growth in 2026 and beyond, and our results this quarter reflect solid execution toward that goal," said Hemsley.

For the third quarter ended September 30, the company's medical loss ratio - the percentage of premiums spent on medical care - stood at 89.9%, which was in line with the company's expectations. Insurers aim for a ratio close to around 80%.

Analysts on average had expected the company to report a ratio of 89.87%, according to LSEG data.

Quarterly revenue at its Optum health services unit was flat year-over-year at $25.9 billion.

Revenue at Optum Rx, UnitedHealth's pharmacy benefit manager, rose 16% to $39.7 billion, helped by higher prescription volumes from new clients and growth in existing clients.

The healthcare giant now sees 2025 adjusted profit per share to be at least $16.25, compared with its previous estimate of at least $16.00. This is higher than the average analyst estimate of $16.20 per share.

On an adjusted basis, the company earned a profit of $2.92 per share for the quarter, beating analysts' average estimate of $2.79.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10